BR112013014061A2 - uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla - Google Patents
uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltiplaInfo
- Publication number
- BR112013014061A2 BR112013014061A2 BR112013014061A BR112013014061A BR112013014061A2 BR 112013014061 A2 BR112013014061 A2 BR 112013014061A2 BR 112013014061 A BR112013014061 A BR 112013014061A BR 112013014061 A BR112013014061 A BR 112013014061A BR 112013014061 A2 BR112013014061 A2 BR 112013014061A2
- Authority
- BR
- Brazil
- Prior art keywords
- improve
- laquinimod
- status
- life
- multiple sclerosis
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
- 229960004577 laquinimod Drugs 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42074210P | 2010-12-07 | 2010-12-07 | |
| US201161542996P | 2011-10-04 | 2011-10-04 | |
| PCT/US2011/063460 WO2012078591A1 (en) | 2010-12-07 | 2011-12-06 | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013014061A2 true BR112013014061A2 (pt) | 2016-09-13 |
Family
ID=46162796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013014061A BR112013014061A2 (pt) | 2010-12-07 | 2011-12-06 | uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla |
Country Status (19)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0617477A2 (pt) * | 2005-10-19 | 2011-07-26 | Teva Pharma | mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica |
| WO2009082471A1 (en) | 2007-12-20 | 2009-07-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| BR112012002124A2 (pt) * | 2009-07-30 | 2015-09-15 | Teva Pharma | tratamento da doença de crohn com laquinimode. |
| WO2011019375A1 (en) | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| EA201290860A1 (ru) * | 2010-03-03 | 2013-04-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата |
| KR20130006640A (ko) * | 2010-03-03 | 2013-01-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
| AU2011274496B2 (en) | 2010-07-09 | 2016-03-10 | Teva Pharmaceutical Industries Ltd. | Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| SG11201401330YA (en) | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| MX2014009889A (es) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
| US20150209346A1 (en) * | 2012-09-27 | 2015-07-30 | Teva Pharmaceutical Industries, Ltd. | Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| MX2015004564A (es) * | 2012-10-12 | 2015-07-21 | Teva Pharma | Laquinimod para producir el daño talamico en la esclerosis multiple. |
| EA201590788A1 (ru) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Аминные соли лахинимода |
| KR20150119227A (ko) * | 2013-02-15 | 2015-10-23 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료 |
| JP2016514162A (ja) | 2013-03-14 | 2016-05-19 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドナトリウムの結晶およびその製造のための改善された方法 |
| WO2014152009A1 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Transdermal formulations of laquinimod |
| BR112016014507A2 (pt) * | 2013-12-20 | 2018-05-22 | Teva Pharma | uso de laquinimod para retardar progressão da doença de huntington |
| EP3094330A4 (en) * | 2014-01-17 | 2017-09-27 | Teva Pharmaceutical Industries Ltd | Treatment of crohn's disease using low doses of laquinimod |
| HK1231413A1 (zh) | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
| CA2964315A1 (en) | 2014-10-16 | 2016-04-21 | Novartis Ag | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| EP3863628B1 (en) * | 2018-10-09 | 2023-12-27 | MediciNova, Inc. | Combination of ibudilast and interferon-beta and methods of using same |
| MX2022000835A (es) * | 2019-07-22 | 2022-02-10 | Actelion Pharmaceuticals Ltd | Metodos para tratar la esclerosis multiple. |
| CN110688373A (zh) * | 2019-09-17 | 2020-01-14 | 杭州绿度信息技术有限公司 | 一种基于逻辑回归的offset方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20160455T1 (hr) * | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| US20060205822A1 (en) * | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| CN101466379B (zh) * | 2006-06-12 | 2012-10-31 | 泰华制药工业有限公司 | 稳定的拉喹莫德的制剂 |
| EP2653873B8 (en) * | 2007-02-08 | 2022-08-24 | Biogen MA Inc. | Compositions and uses for treating Multiple Sclerosis |
| NZ597378A (en) * | 2009-06-19 | 2014-08-29 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
-
2011
- 2011-12-06 PE PE2013001357A patent/PE20140872A1/es not_active Application Discontinuation
- 2011-12-06 JP JP2013543255A patent/JP2013544887A/ja active Pending
- 2011-12-06 UA UAA201308448A patent/UA111959C2/uk unknown
- 2011-12-06 BR BR112013014061A patent/BR112013014061A2/pt not_active Application Discontinuation
- 2011-12-06 NZ NZ611628A patent/NZ611628A/en not_active IP Right Cessation
- 2011-12-06 MX MX2013006464A patent/MX2013006464A/es unknown
- 2011-12-06 KR KR1020137017362A patent/KR20130124518A/ko not_active Ceased
- 2011-12-06 AU AU2011338647A patent/AU2011338647A1/en not_active Abandoned
- 2011-12-06 CA CA2820586A patent/CA2820586A1/en not_active Abandoned
- 2011-12-06 PH PH1/2013/501193A patent/PH12013501193A1/en unknown
- 2011-12-06 CN CN201180060414.8A patent/CN103260624B/zh not_active Expired - Fee Related
- 2011-12-06 EP EP11846599.6A patent/EP2648732A4/en not_active Withdrawn
- 2011-12-06 US US13/312,284 patent/US20120142730A1/en not_active Abandoned
- 2011-12-06 EA EA201390827A patent/EA201390827A1/ru unknown
- 2011-12-06 SG SG10201509831XA patent/SG10201509831XA/en unknown
- 2011-12-06 WO PCT/US2011/063460 patent/WO2012078591A1/en not_active Ceased
- 2011-12-06 SG SG2013042403A patent/SG190449A1/en unknown
-
2013
- 2013-06-05 CL CL2013001602A patent/CL2013001602A1/es unknown
- 2013-06-10 ZA ZA2013/04237A patent/ZA201304237B/en unknown
-
2016
- 2016-12-26 JP JP2016251360A patent/JP2017095476A/ja active Pending
-
2017
- 2017-02-22 IL IL250726A patent/IL250726A0/en unknown
- 2017-03-28 AU AU2017202055A patent/AU2017202055A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013544887A (ja) | 2013-12-19 |
| EP2648732A1 (en) | 2013-10-16 |
| CL2013001602A1 (es) | 2013-10-25 |
| MX2013006464A (es) | 2013-07-29 |
| EA201390827A1 (ru) | 2013-12-30 |
| IL250726A0 (en) | 2017-04-30 |
| WO2012078591A8 (en) | 2012-08-02 |
| NZ611628A (en) | 2015-06-26 |
| UA111959C2 (uk) | 2016-07-11 |
| SG190449A1 (en) | 2013-07-31 |
| AU2011338647A1 (en) | 2013-07-04 |
| JP2017095476A (ja) | 2017-06-01 |
| AU2011338647A8 (en) | 2013-09-05 |
| PE20140872A1 (es) | 2014-08-09 |
| US20120142730A1 (en) | 2012-06-07 |
| WO2012078591A1 (en) | 2012-06-14 |
| CA2820586A1 (en) | 2012-06-14 |
| PH12013501193A1 (en) | 2013-07-15 |
| ZA201304237B (en) | 2014-08-27 |
| KR20130124518A (ko) | 2013-11-14 |
| AU2017202055A1 (en) | 2017-04-20 |
| CN103260624B (zh) | 2015-06-03 |
| CN103260624A (zh) | 2013-08-21 |
| SG10201509831XA (en) | 2015-12-30 |
| EP2648732A4 (en) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250726A0 (en) | Use of lequinimod to reduce fatigue, improve function and improve quality of life in multiple sclerosis patients | |
| CO6910171A2 (es) | Implemento de cuidado bucal y cabeza de repuesto para el mismo | |
| EP2717922A4 (en) | GENE THERAPY VECTORS FOR ADRENOLEUCODYSTROPHY AND ADRENOMYELONEUROPATHY | |
| BR112013023928A2 (pt) | componente lubrificante; lubrificante; uso do componente lubrificante; método de redução de fricção; e método de redução de desgaste | |
| BRPI1012638A2 (pt) | métodos e intermediários para preparar agentes farmacêuticos | |
| HUE050189T2 (hu) | Szubsztituált benzaldehid-vegyületek és alkalmazási módszereik a szöveti oxigenizáció növelésében | |
| CO6821883A2 (es) | Nuevos moduladores y métodos para su uso | |
| PT2782584T (pt) | Preparações e terapias de substituição para hormonoterapias naturais combinadas | |
| BRPI1014464A2 (pt) | 4-ciano-3-benzoilamino-n-fenil-benzamidas para uso no controle de pragas | |
| BR112014013682A2 (pt) | composição para cuidado pessoal | |
| HUE045656T2 (hu) | PHF-tau elleni ellenanyagok és alkalmazásuk | |
| CL2013002601A1 (es) | Uso de 1-desoxigalactonojirimicina y una terapia de reemplazo de enzimas con alfa-gal a para tratar la enfermedad de fabry. | |
| HRP20171579T8 (hr) | Antigljivična sredstva i njihova upotreba | |
| EP2686514B8 (en) | Integral wear pad and method | |
| PT2739268T (pt) | Método e formulação para inalação | |
| FI20100196L (fi) | Matalanikkelinen austeniittinen ruostumaton teräs ja teräksen käyttö | |
| FI20110053A0 (fi) | Menetelmä laivan käyttämiseksi uudella tavalla ja monikäyttöinen laiva | |
| BR112014014242A2 (pt) | método de fortalecimento de fibras de cabelo e uso de uma composição para cabelo | |
| ZA201400562B (en) | Axmi205 variant proteins and methods for their use | |
| BR112014010739A2 (pt) | agentes terapêuticos e uso dos mesmos | |
| BR112014014004A2 (pt) | métodos e composições para redução de gordura corporal e adipócitos | |
| BR112012028719A2 (pt) | composição de tratamento de superfície dura, método para fornecer um efeito antimicrobiano a uma superfície dura e uso de uma combinação | |
| PL2786986T3 (pl) | Nowa pochodna benzamidu i jej zastosowanie | |
| BR112013016537A2 (pt) | método para formar um laminado elastomérico e método para fabricar uma peça de vestuário de cuidados pessoais | |
| IL229631A0 (en) | Test of lysyl oxidase-like 2 and methods of using it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |